ArticleCell death discovery2026
Taurine is a natural suppressor of urea cycle via targeting ASL.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SIRT5-dependent regulation of ASL controls arginine metabolism and T cell function.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) has become the leading cause of global cancer-related mortality, which raises the demand for optimized therapeutic routes. The semi-essential micronutrient taurine has been gradually identified as a pivotal player linked to various diseases. Nevertheless, the metabolic impacts of taurine on hepatocellular carcinoma remain elusive. Here, we report that taurine is a negative regulator of urea cycle, thereby exerting a suppressive effect on growth of HCC tumors. Mechanistically, argininosuccinate lyase (ASL) is uncovered as the main target of taurine in repressing urea cycle of HCC cell lines. Furthermore, Fos proto-oncogene (FOS) functions as the transcription factor of ASL, which is significantly reduced upon taurine treatment. Physiologically, FOS-ASL axis is required for metabolic effects of taurine and contributes to growth of HCC tumors. Expression of ASL correlates with the inhibitory effect of taurine. Ultimately, synergistic blockade of glutaminolysis and urea cycle indicates that taurine is sufficient to substantially enhance the efficacy of the glutaminase GLS1 inhibitor in management of hepatocellular carcinoma. Collectively, these findings not only illustrate the metabolic mechanism of taurine in controlling growth of HCC tumors, but also create a promising route for utilization of taurine in clinic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.